Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUS NASDAQ:ACTU NASDAQ:AUTL NASDAQ:PHVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.36+1.9%$4.19$2.70▼$5.10$835.81M1.09921,883 shs786,823 shsACTUActuate Therapeutics$7.20-0.7%$7.52$5.47▼$11.99$167.35M-0.2371,047 shs68,495 shsAUTLAutolus Therapeutics$1.53+2.0%$1.55$1.11▼$4.69$407.20M1.842.95 million shs1.27 million shsPHVSPharvaris$22.990.0%$23.20$11.51▼$26.33$1.20B-2.77236,289 shs459,454 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma+1.87%-1.13%-2.90%+35.40%+7.39%ACTUActuate Therapeutics-0.69%-3.74%+2.56%-0.83%-4.76%AUTLAutolus Therapeutics+2.00%-5.56%-1.92%-39.29%-65.77%PHVSPharvaris-0.04%+8.85%-5.86%+11.49%+3.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.36+1.9%$4.19$2.70▼$5.10$835.81M1.09921,883 shs786,823 shsACTUActuate Therapeutics$7.20-0.7%$7.52$5.47▼$11.99$167.35M-0.2371,047 shs68,495 shsAUTLAutolus Therapeutics$1.53+2.0%$1.55$1.11▼$4.69$407.20M1.842.95 million shs1.27 million shsPHVSPharvaris$22.990.0%$23.20$11.51▼$26.33$1.20B-2.77236,289 shs459,454 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma+1.87%-1.13%-2.90%+35.40%+7.39%ACTUActuate Therapeutics-0.69%-3.74%+2.56%-0.83%-4.76%AUTLAutolus Therapeutics+2.00%-5.56%-1.92%-39.29%-65.77%PHVSPharvaris-0.04%+8.85%-5.86%+11.49%+3.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 2.50Moderate Buy$5.0014.68% UpsideACTUActuate Therapeutics 2.50Moderate Buy$20.33182.41% UpsideAUTLAutolus Therapeutics 2.71Moderate Buy$9.12496.08% UpsidePHVSPharvaris 2.50Moderate Buy$37.1761.66% UpsideCurrent Analyst Ratings BreakdownLatest ACTU, PHVS, ABUS, and AUTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025PHVSPharvarisWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025ABUSArbutus BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025ACTUActuate TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025AUTLAutolus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/20/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.0010/15/2025PHVSPharvarisHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.0010/15/2025PHVSPharvarisHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.0010/9/2025PHVSPharvarisBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Neutral$16.00 ➝ $27.0010/8/2025ABUSArbutus BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ACTUActuate TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025AUTLAutolus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.17M135.46N/AN/A$0.51 per share8.55ACTUActuate TherapeuticsN/AN/AN/AN/A$0.01 per shareN/AAUTLAutolus Therapeutics$10.12M40.24N/AN/A$1.61 per share0.95PHVSPharvarisN/AN/AN/AN/A$5.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$69.92M-$0.29N/AN/AN/A-352.24%-59.28%-44.11%11/5/2025 (Estimated)ACTUActuate Therapeutics-$27.28M-$1.17N/A∞N/AN/AN/A-281.83%N/AAUTLAutolus Therapeutics-$220.66M-$0.84N/AN/AN/AN/A-56.18%-29.61%11/11/2025 (Estimated)PHVSPharvaris-$145.24M-$3.36N/AN/AN/AN/A-69.09%-63.34%11/12/2025 (Estimated)Latest ACTU, PHVS, ABUS, and AUTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025PHVSPharvaris-$0.80N/AN/AN/AN/AN/A11/11/2025Q3 2025AUTLAutolus Therapeutics-$0.24N/AN/AN/A$21.08 millionN/A11/5/2025Q3 2025ABUSArbutus Biopharma-$0.0460N/AN/AN/A$1.31 millionN/A8/14/2025Q2 2025ACTUActuate Therapeutics-$0.19-$0.30-$0.11-$0.30N/AN/A8/12/2025Q2 2025AUTLAutolus Therapeutics-$0.24-$0.18+$0.06-$0.18$12.92 million$13.50 million8/12/2025Q2 2025PHVSPharvaris-$0.87-$0.94-$0.07-$0.94N/AN/A8/6/2025Q2 2025ABUSArbutus Biopharma-$0.02$0.01+$0.03$0.01$2.21 million$10.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AACTUActuate TherapeuticsN/AN/AN/AN/AN/AAUTLAutolus TherapeuticsN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A20.5320.53ACTUActuate TherapeuticsN/A0.730.73AUTLAutolus TherapeuticsN/A8.438.07PHVSPharvarisN/A8.338.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%ACTUActuate TherapeuticsN/AAUTLAutolus Therapeutics72.83%PHVSPharvarisN/AInsider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%ACTUActuate Therapeutics69.34%AUTLAutolus Therapeutics25.70%PHVSPharvaris11.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.70 million152.78 millionOptionableACTUActuate Therapeutics1023.24 million7.13 millionN/AAUTLAutolus Therapeutics330266.14 million197.74 millionOptionablePHVSPharvaris3052.29 million46.10 millionNot OptionableACTU, PHVS, ABUS, and AUTL HeadlinesRecent News About These CompaniesPharvaris (NASDAQ:PHVS) Sees Large Volume Increase - Here's WhyOctober 25 at 5:26 PM | marketbeat.comSix new option listings on October 24thOctober 24 at 12:40 PM | msn.com3 Best Stocks to Buy Now, 10/23/2025, According to Top AnalystsOctober 23 at 12:26 AM | msn.comPharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific MeetingOctober 23 at 7:01 AM | globenewswire.comTD Asset Management Inc Buys 21,388 Shares of Pharvaris N.V. $PHVSOctober 22 at 3:51 AM | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Up 10.3% - Should You Buy?October 20, 2025 | marketbeat.comPharvaris N.V. (NASDAQ:PHVS) Receives Average Rating of "Moderate Buy" from AnalystsOctober 19, 2025 | americanbankingnews.comPharvaris (NASDAQ:PHVS) Research Coverage Started at HC WainwrightOctober 18, 2025 | americanbankingnews.comQ3 Earnings Forecast for Pharvaris Issued By HC WainwrightOctober 17, 2025 | marketbeat.comHC Wainwright & Co. Initiates Coverage of Pharvaris N.V. (PHVS) with Buy RecommendationOctober 16, 2025 | msn.comPharvaris (NASDAQ:PHVS) Stock Rating Upgraded by HC WainwrightOctober 16, 2025 | marketbeat.comPharvaris initiated with a Buy at H.C. WainwrightOctober 15, 2025 | msn.comPharvaris (NASDAQ:PHVS) Shares Gap Up - Time to Buy?October 15, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Sees Strong Trading Volume - Should You Buy?October 14, 2025 | marketbeat.comPharvaris N.V. (NASDAQ:PHVS) Given Average Recommendation of "Hold" by AnalystsOctober 14, 2025 | marketbeat.comPharvaris N.V. (PHVS) Presents at 2025 HAE International (HAEi) Regional Conference EMEA - SlideshowOctober 13, 2025 | seekingalpha.comB of A Securities Upgrades Pharvaris N.V. (PHVS)October 10, 2025 | msn.comPharvaris (NASDAQ:PHVS) Raised to Neutral at Bank of AmericaOctober 10, 2025 | marketbeat.comWeiss Ratings Reiterates Sell (D-) Rating for Pharvaris (NASDAQ:PHVS)October 10, 2025 | marketbeat.comBofA upgrades Pharvaris to Neutral on potential label expansionOctober 9, 2025 | msn.comPharvaris (NASDAQ:PHVS) Shares Gap Down - Here's What HappenedOctober 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025Intel's Turnaround Hits Hyperspeed With A New 52-Week HighBy Jeffrey Neal Johnson | October 17, 2025This AI Chip Giant Could Be the Market’s Next Big WinnerBy Gabriel Osorio-Mazilli | October 17, 2025ACTU, PHVS, ABUS, and AUTL Company DescriptionsArbutus Biopharma NASDAQ:ABUS$4.36 +0.08 (+1.87%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$4.38 +0.02 (+0.44%) As of 10/24/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Actuate Therapeutics NASDAQ:ACTU$7.20 -0.05 (-0.69%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$7.20 0.00 (-0.07%) As of 10/24/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Autolus Therapeutics NASDAQ:AUTL$1.53 +0.03 (+2.00%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.54 +0.01 (+0.98%) As of 10/24/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Pharvaris NASDAQ:PHVS$22.99 -0.01 (-0.04%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$22.90 -0.09 (-0.39%) As of 10/24/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
